You just read:

Neuraltus Pharmaceuticals and the University of Hawaii at Manoa Announce Initiation of Phase 1b Study of NP001 in Patients with Mild-to-Moderate Alzheimer's Disease

News provided by

Neuraltus Pharmaceuticals, Inc.

Sep 13, 2017, 08:00 ET